Replies to post #1332 on GTC Biotherapeutics (fka GTCB)

[keitern]

Thanks. NovoSeven then has no exclusivity for rhFVIIa or it must be a class of drug. This begs the following questions from my lay-person's point of view:

1) Does the fact that rhFVIIa is currently in use mitigate some of the risk of taking a new drug to trials and final acceptance?
2) In general, does GTCB's obvious tact of seeking development and approval of drugs that are both expensive to produce traditionally and have been previously approved in another form or at least have been validated prior mitigate some of the risk vis. another typical bio-tech that is seeking some entirely new treatment?
3) Do you think that GTCB is relatively confident that it can produce the rhFVIIa from its technology? I mean, they seem to have a high level of confidence that they can produce a given protein from milk.

Thanks